Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
193 hedge funds and large institutions have $1.36B invested in Revance Therapeutics, Inc. in 2022 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 79 increasing their positions, 52 reducing their positions, and 25 closing their positions.
172% more call options, than puts
Call options by funds: $156M | Put options by funds: $57.2M
52% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 25
52% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 52
6% more funds holding
Funds holding: 182 → 193 (+11)
20% less capital invested
Capital invested by funds: $1.7B → $1.36B (-$341M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$32.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$22M |
| 3 |
Jennison Associates
New York
|
+$21.8M |
| 4 |
BlackRock
New York
|
+$21.5M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$20.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$18.2M |
| 2 |
BAMCO Inc
New York
|
-$10.6M |
| 3 |
JP Morgan Chase
New York
|
-$9.97M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$8.77M |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$8.33M |
RVNC Hedge Fund Activity: Q4 2022 in Review
193 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2022, worth a combined $1.36B — down 20% from $1.7B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new RVNC positions and 25 closed out — a net gain of 13 holders — while 79 added to existing stakes and 52 trimmed.
The largest buyer was Capital World Investors, adding an estimated $32.7M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $18.2M.
- 193 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2022, up from 182 in Q3 2022.
- Funds reported $1.36B of Revance Therapeutics, Inc. stock for Q4 2022, down 20% quarter-over-quarter.
- 38 funds opened new Revance Therapeutics, Inc. positions in Q4 2022 and 25 closed out, a net change of +13 holders.
- The largest Revance Therapeutics, Inc. buyer in Q4 2022 was Capital World Investors, an estimated $32.7M added.
- The largest Revance Therapeutics, Inc. seller in Q4 2022 was Jacobs Levy Equity Management, an estimated $18.2M sold.
Based on aggregated 13F filings for Q4 2022.